SEARCH

SEARCH BY CITATION

Professor R E Pounder, Co-Editor

None to declare.

Professor N J Talley, Co-Editor

Professor Talley acts or has acted as a consultant for ARYx Therapeutics, Accredit Ed, Astellas Pharma Inc., Boehringer-Ingelheim, Care Capital, ConCERT Pharma, Edusa Pharma, Falk Pharma, Forest, Focus Medical, Ironwood Pharmaceuticals, Janssen Cilag, Johnson & Johnson, Medscape, Meritage Pharma, NicOx, Pfizer, Prometheus, Procter and Gamble, Salix Pharma, Sanofi-Aventis, Shire, Theravance, Tranzyme, XenoPort and Zeria. He has also received financial support for research from Falk, Forest, Janssen and Takeda. He is a key opinion leader with Doyen Medical Inc., and has lectured at CME meetings sponsored by Salix and Astra Zeneca.

Professor J M Rhodes, Associate Editor

Professor Rhodes is a member of advisory boards for Atlantic, Procter & Gamble and Falk, has received speaking honoraria from Abbott, Falk, Ferring, Glaxo Smith Kline, Procter & Gamble, Schering Plough, Shire and Wyeth and, with the University of Liverpool and Provexis UK, holds a patent for use of a soluble fibre preparation as maintenance therapy for Crohn's disease.

Professor P Martin, Associate Editor

Professor Martin has received grant support from Gilead, BMS, Genentech, and Vertex. He served on paid advisory boards for BMS, Salix, Genentech, Merck and Vertex. He was a speaker for BMS and Vertex.

Professor J-F Colombel, Associate Editor

During the last 3 years, Professor Colombel has received consulting fees from, or served on paid advisory boards for Abbott Laboratories, Bristol Meyers Squibb, Cellerix SL, Centocor, Chemocentryx Inc., Cosmo Technologies Ltd, Danone France, Elan Pharmaceuticals Inc., Genentech, Giuliani SPA, Given Imaging, GlaxoSmithKline, HutchinsonMediPharma, Janssen, Lexicon, Merck and Co. Inc., Merieux Alliance, Millenium Pharmaceuticals Inc., NeoVacs SA, Ocerra Therapeutics Inc. (previously named Renovia Inc.), Pfizer Inc., Prometheus, Ribo Vacs Biotech, Sanofi-Aventis, Schering Plough Corporation, Shire Pharmaceuticals, Synta Pharmaceutical Corporation, Takeda, Teva Pharmaceuticals and Petah Tikva, Therakos, Tillots, UCB Pharma (previously named Celltech Therapeutics Ltd) and Wyeth Pharmaceuticals.

He has also received lecture fees from speaking at continuing medical education events indirectly sponsored by a commercial sponsor from Abbott Laboratories, Centocor, Elan Pharmaceuticals Inc., Falk Pharma, Ferring, Given Imaging, Merck and Co., Schering Plough Corporation, Shire Pharmaceuticals, Tillots and UCB Pharma. In addition, during the last 4 years, he has received grant support from Astra-Zeneca, Ferring, Giuliani SPA, Lesaffre, Roquette, Prometheus, Schering Plough Corporation and UCB Pharma.

Professor Colombel also has stock ownership in Intestinal Biotech Development, Lille, France.

Professor M B Fennerty, Associate Editor

Professor Fennerty is an Editor of Journal Watch Gastroenterology. He is the Past-President of the American Society for Gastrointestinal Endoscopy, and is a member of Medco's National Pharmacy and Therapeutics Committee. He acts as a consultant for the FDA's Gastroenterology and Urology Devices Committee, Oncoscope, Aptalis and Meridian Bioscience. During the last 2 years, he has also provided expert testimony in patent litigation related to a Merck product.

Professor S V Kane, Associate Editor

Professor Kane has received grant/research support from Elan Pharmaceuticals, Shire Pharmaceuticals and UCB Pharma. She also acts as a consultant for Abbott Laboratories, Cosmo Pharmaceuticals, Elan Pharmaceuticals, Janssen, Millennium Pharmaceuticals Inc., Shire Pharmaceuticals, and UCB Pharma. Professor Kane serves as an ad hoc contributor to WedMD, and is on the FDA Safety Advisory Board for Gastroenterology.

Professor Peter C Hayes, Associate Editor

Professor Hayes recently acted in an advisory capacity, been paid to speak at meetings or had travel support with Falk, Gilead, Gore, Janssen, MSD, Roche and Pfizer.

Dr Alex Ford, Associate Editor

Dr Ford has acted as a consultant/speaker for GE Healthcare, MSD and Shire Pharmaceuticals.

Policy

  1. Top of page
  2. Policy

If an Editor has a potential conflict of interest with the contents of a manuscript, usually that manuscript will be transferred to another Editor. Occasionally, because of the specialist nature of some manuscripts and limited experience of the other Editors, the manuscript may remain under the supervision of the original specialist Editor, who will confer with other Editors before making a decision.

16th April 2012